ForSight VISION5 has closed a $15m Series C round led by H.I.G. BioVentures, alongside returning investors Morgenthaler Ventures, Versant Ventures, Technology Partners, and Delphi Ventures.
The company was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs. It is focused on developing non-invasive products that replace eye drops and provide sustained therapy for major anterior segment eye diseases
As part of the deal Aaron Davidson of H.I.G. BioVentures will join the company’s board of directors.
He said, “We are very enthusiastic about the ForSight VISION5 investment opportunity. We believe that millions of patients with glaucoma and ocular hypertension will benefit from the company’s lead product candidate and we also see the potential to broaden the company’s impact as it develops additional products.”
H.I.G. BioVentures is the dedicated life-science investment affiliate of private equity investment firm H.I.G Capital. BioVentures invests in a broad range of life sciences opportunities across sectors and stages, principally in companies developing therapeutic drugs, medical devices, and diagnostics for significant unmet medical needs. With approximately $400m in committed capital, H.I.G. BioVentures invests approximately $3m to $40m per company.
Copyright © 2014 AltAssets